Andera Partners

Andera Partners, established in 2001, is a Paris-based private equity firm with a 250-year heritage tracing back to the Rothschild family. The firm manages over €2 billion, focusing on investments in unlisted companies across France and internationally. Andera Partners specializes in life sciences, growth capital, and sponsorless mezzanine debt, aiming to create long-term value for its investors.

Jérémy Afriat

Investment Manager

Nicolas Aftimos

Director

Cécile Ah-Fa

Investment Manager

Guy Auger

Partner

Natali Romero Barrios

Investment Manager

Augustin Bayvet

Senior Investment Manager

Sabrina Bazire

Invesment Director

Vincent Bazzocchi

Director, Andera MidCap team

Stéphane Bergez

Partner and Head of Andera Acto

Jean-Baptiste Bessieres

Partner

Vincent Botton

Investment Manager

Leopold Brichard

Partner

Xavier Buisson

Director

Andrei Buzdugan

CFO

Victor Cabaud

Senior Investment Manager

Carlo Cartapani

Senior Investment Manager

Sylvain Charignon

Partner

Elyes Chouaieb

Investment Director

Coquille, Marie

Senior Investment Manager

Vincent Croci

Senior Investment Manager

Nicolas Debonneuil

Investment Director

Henri Elbaz

Director, Development

Pierre Flin

Investment Manager

Alexandre Foulon

Investment Director

Florian Gerard-Mercier Ph.D

Investment Director

Francesco Gonzaga

Partner

Antoine Guérillon

Investment Manager

Ana Flavia Guizani

Investors Relations Analyst

Louis Hamon

Advising Partner

Marianne Harle

Partner, Andera Croissance team

Thierry Hercend

Venture Partner

Loan Hoang-Sayag

Venture Partner, Andera Life Sciences team

Sofia Ioannidou

Partner

Julia Joannot

Senior Investment Manager

Christine Martinovic

Director

Francois Xavier Mauron

Partner

Francois-Xavier Mauron

Partner, Andera MidCap team

Thibault Menel

Investment Director

Arthur Milliard

Director

Romain Ohayon

Associate

Aurélie Owona

Investment Director

Mathieu Pieronne

Director

Pierre-Yves Poirier

Partner

Luca Ravano

Partner

Alban Ravinet

Investment Manager

Albane Richard

Analyst

Prune Des Roches

Co-Founder, Associate, Andera Smart Infra and Partner

Etienne Rossignol

Investment Director

Aneta Sottil

Partner

Antoine Soucaze

Director

Quentin Tarasconi

Senior Investment Manager

Hanna Tayeb

Senior Investment Manager

Laurent Tourtois

Investment Director

Yuexin Yu

Director

Past deals in Southwestern Europe

EG 427

Series B in 2025
EG 427 is a French biotechnology company that specializes in pinpoint gene therapy, aimed at treating disorders related to spinal cord injuries. The company utilizes HSV-1-based vectors, leveraging the natural characteristics of the Herpes Simplex Virus 1 to establish lifelong latency in peripheral neurons. This innovative approach allows for targeted and sustained expression of therapeutic genes, providing a potential cure for severe, chronic, and localized conditions, such as neurogenic bladder disorders resulting from spinal cord injuries. By focusing on this advanced gene therapy technique, EG 427 seeks to improve treatment outcomes for patients suffering from these debilitating conditions.

Ayming

Acquisition in 2025
Ayming is a management consulting firm headquartered in Levallois, France, that focuses on optimizing operational performance for its clients. The company provides a range of services, including consulting on human resources costs, tax strategies, operational costs optimization, software solutions, and energy and environmental issues. Additionally, Ayming offers advisory services related to work contributions and wage audits. By leveraging these diverse consulting offerings, Ayming aims to help organizations enhance their efficiency and overall performance while effectively managing social costs associated with taxes and financial operations.

ENYO Pharma

Series C in 2024
ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Andera Partners

Series A in 2023
Andera Partners, established in 2001, is a Paris-based private equity firm with a 250-year heritage tracing back to the Rothschild family. The firm manages over €2 billion, focusing on investments in unlisted companies across France and internationally. Andera Partners specializes in life sciences, growth capital, and sponsorless mezzanine debt, aiming to create long-term value for its investors.

HR Path

Private Equity Round in 2022
HR Path is a global consultancy focused on human capital management, with a team of over 500 consultants operating across North America, Europe, and the Middle East. The company specializes in HR Systems Integration, HR Outsourcing, and HR Business Consulting, offering a range of services to support businesses in their digital transformation. HR Path is an authorized reseller of various HR software solutions, including those from SAP, SuccessFactors, and Oracle HCM, among others. In addition to reselling, the company has developed its own HR software solutions, such as BiHRdy, a business intelligence tool; Pandore, a packaged HR, payroll, and time management solution; and Geef, a talent management system. The client portfolio includes a mix of large corporations, including CAC 40-listed companies, as well as small and medium-sized enterprises and public sector organizations, reflecting its versatility in meeting diverse client needs.

Lhyfe

Venture Round in 2022
Lhyfe is a company based in Nantes, France, that specializes in the design, development, and operation of industrial sites for the production of green hydrogen using renewable energy sources such as wind and solar power. Founded in 2017, Lhyfe aims to provide substantial quantities of clean and affordable hydrogen, facilitating the transition of various industrial sectors and transportation towards a sustainable energy framework. The company focuses on two primary markets: heavy mobility, including trucks, buses, trains, and potentially maritime and air transport, as well as industrial applications, targeting industries such as chemistry, steel, and glass production. By integrating its production facilities with available renewable energy sources, Lhyfe ensures a minimal environmental footprint while addressing the urgent need to reduce greenhouse gas emissions.

Atlantic Therapeutics Limited

Venture Round in 2021
Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

MedLumics

Venture Round in 2021
Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

Sogetrel

Acquisition in 2021
Sogetrel, S.A.S. is a prominent company specializing in the design, deployment, and maintenance of network infrastructures and digital communication solutions. Established in 1985 and headquartered in Issy les Moulineaux, France, Sogetrel operates branches in Belgium and Switzerland. The company provides a range of services, including the integration of telecommunications networks, IP security systems for video surveillance and access control, and support for smart city projects. Sogetrel serves a diverse clientele across various sectors such as telecommunications, public authorities, defense, transport, and utilities. By focusing on the development of very high-speed networks and offering both customized and turnkey solutions, Sogetrel aims to enhance the quality of life for citizens while promoting efficiency and sustainability in the regions it serves.

Sirsa

Venture Round in 2021
Sirsa, founded in 2014 and based in Paris, France, is a consulting firm focused on sustainable transformation. The company specializes in evaluating existing processes, analyzing risks, and defining strategies to enhance operational sustainability. Sirsa provides a software-as-a-service platform for measuring companies' extra-financial footprint and impacts. It assists clients in implementing strategic initiatives, managing action plans, reporting results, and ensuring compliance with regulations. The firm serves a diverse range of industries, including aerospace, defense, food products, electrical equipment, healthcare, energy, medical supplies, environmental services, and software, among others.

MasterGrid

Private Equity Round in 2019
MasterGrid, based in Grenoble, France, specializes in the manufacture and supply of high voltage electrical equipment tailored for the commercial and industrial sectors. Established in 2019, the company produces a range of products including high, medium, and low-voltage equipment designed for the distribution, protection, control, and management of electrical systems. In addition to manufacturing, MasterGrid offers equipment handling services, ensuring that clients receive safe and durable products that enhance performance and efficiency.

Olaqin

Acquisition in 2019
Olaqin is a healthcare service provider based in Suresnes, France, specializing in e-health solutions for healthcare professionals. The company distinguishes itself by offering tailored services to various sectors within the healthcare industry. Olaqin operates through a value-added distribution network, supplying SESAM-Vitale readers and associated software indirectly, while also engaging directly with hospitals and pharmacies via public and service contracts. Its offerings include centralized payment systems, securing electronic care sheets, updating Vitale cards, and ensuring secure access to online medical records. These services enhance operational efficiency for healthcare professionals by providing essential technological and management support.

Ellisphere

Acquisition in 2019
Ellisphere is a business intelligence company that provides decision-making information to executives and decision-makers in France and internationally through its BIGnet network. The company offers a comprehensive platform that delivers economic and financial information about trading partners, as well as insights into customer and supplier portfolios. Additionally, it provides guidance on legislation and regulatory compliance, helping businesses to develop effective customer-base strategies. By focusing on information management and data marketing, Ellisphere supports organizations in promoting and sustaining their growth and development.

HR Path

Private Equity Round in 2019
HR Path is a global consultancy focused on human capital management, with a team of over 500 consultants operating across North America, Europe, and the Middle East. The company specializes in HR Systems Integration, HR Outsourcing, and HR Business Consulting, offering a range of services to support businesses in their digital transformation. HR Path is an authorized reseller of various HR software solutions, including those from SAP, SuccessFactors, and Oracle HCM, among others. In addition to reselling, the company has developed its own HR software solutions, such as BiHRdy, a business intelligence tool; Pandore, a packaged HR, payroll, and time management solution; and Geef, a talent management system. The client portfolio includes a mix of large corporations, including CAC 40-listed companies, as well as small and medium-sized enterprises and public sector organizations, reflecting its versatility in meeting diverse client needs.

Tournus Equipement

Private Equity Round in 2019
Tournus Equipement, S.A.S. is a manufacturer based in Tournus, France, specializing in stainless steel environments for professional kitchens and supermarket fish counters. The company provides a wide range of products, including mobile and modular kitchens, regeneration ovens, warmers, sterilizing cabinets, and various kitchen units. It also designs and manufactures equipment such as trolleys, containers, wash-basins, dishwashing equipment, and shelving products. Tournus Equipement serves diverse sectors, including canteens, restaurants, bakeries, supermarkets, and transport catering services. In addition to its manufacturing capabilities, the company offers joint design, installation, and express delivery services, catering to the specific needs of its clients. Founded in 1910, Tournus Equipement is known for its commitment to quality and durability in commercial kitchen solutions.

Verbraeken Infra

Acquisition in 2019
Verbraeken Infra NV is a Belgian company specializing in the construction and renovation of underground and overhead infrastructure networks across Europe and North Africa. Founded in 1966 and based in Temse, Belgium, the company provides a wide range of services, including earth and roadworks, pipeline and sewer installation, and electrical works such as the installation of underground transmission cables and public lighting maintenance. Verbraeken Infra also engages in the installation of traditional copper and coaxial cables, as well as advanced techniques like horizontal directional drilling and pipe jacking. With approximately 1,000 employees and annual sales of €140 million, the company has expanded its operations in France, Germany, and the Benelux region, strengthening its market position in Belgium and enhancing its capacity to serve gas, water, electricity, and telecom companies.

Atlantic Therapeutics Limited

Series B in 2019
Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

The Bioclinic Group

Private Equity Round in 2018
Bioclinic operates a network of medical analysis laboratories in the Ile-de-France region, serving health professionals, hospitals, clinics, care centers, and retirement homes. Founded in 1995 and based in Paris, the company specializes in areas such as molecular biology, genetics, antibiotic resistance, and reproductive health. By focusing on these fields, Bioclinic aims to provide clients and their patients with enhanced medical diagnostic results.

Atlantic Therapeutics Limited

Private Equity Round in 2018
Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

Skill & You

Acquisition in 2018
Skill & You is the leading provider of vocational e-learning in France, focusing on delivering real results and recognized qualifications such as BAC PRO, BEP, BP, BTS, and CAP. The company operates an online education and distance learning platform that offers customized courses tailored to the specific needs of learners and industries. By leveraging innovative pedagogy and adaptable educational technology, Skill & You empowers individuals to acquire professional skills necessary for career advancement or personal development. With a strong track record of successful educational initiatives, Skill & You is committed to addressing the challenges of employment by equipping learners with the skills needed to transform their lives.

ENYO Pharma

Series B in 2018
ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Biogroup-LCD

Debt Financing in 2018
BIOGROUP-LCD, a major French player in local medical biology, supports more than 20,000 patients every day and offers more than 2000 routine and specialized daily examinations, based on performance and technological innovation. Partner at every moment between the patient and the medical profession, your laboratory participates in the screening, diagnosis, monitoring and prognosis of the most common pathologies to the most demanding, throughout your course of care. BIOGROUP-LCD develops for this purpose all its human and technological resources. The team of qualified, qualified medical biologists follows continuous and regular training.

TimeOne

Acquisition in 2017
TimeOne, established in 2016, is a global marketing services group formed by merging Public-Idées and Place des Leads. Headquartered in France with operations across Europe, Asia, South Africa, and South America, the company specializes in providing comprehensive digital marketing solutions. TimeOne's core offerings include programmatic advertising, native content marketing, performance-based campaigns, digital marketplace management, publishing services, and mobile marketing strategies. The company is renowned for its innovative approach to prescriptive marketing, driven by a robust data management platform (DMP) and a strong focus on research and development.

Globe Groupe

Private Equity Round in 2017
GLOBE Groupe sa is a Paris-based advertising agency that specializes in strategic marketing and communication services. The company focuses on shopper marketing to create impactful consumer experiences that drive sales. It offers a range of services including strategic planning, non-media planning, talent casting, recruitment, training, payroll, and logistics such as storage, dispatch, and cold-chain management. GLOBE Groupe also implements marketing activation campaigns and provides tools for performance measurement, utilizing key performance indicators to assess the effectiveness of its strategies. The firm caters to various sectors including consumer goods, media, retail, and recruitment, ensuring that its clients can adapt to the evolving landscape of consumer behavior and promotional messaging. Through its secure online platform, myGLOBE, clients can monitor operations in real-time, enhancing transparency and communication throughout the marketing process.

Allodiagnostic

Acquisition in 2017
Allodiagnostic SAS, based in Paris, France, specializes in providing essential real estate diagnostics, including assessments for termites, electrical systems, and energy performance. Founded in 2001, the company caters to private individuals during the sale or rental of properties. It serves as a key resource for both consumers and real estate professionals, offering tailored solutions to meet various diagnostic requirements. As of July 2017, Allodiagnostic operates as a subsidiary of Edmond de Rothschild (France).

Intech

Private Equity Round in 2017
Intech is a leading manufacturer of orthopedic instruments and implants dedicated to enhancing patient outcomes. Operating with a workforce of around 1,000 employees globally, the company provides comprehensive manufacturing solutions to medical device original equipment manufacturers (OEMs). Intech specializes in a wide range of surgical tools, including implants, sterilization cases, and trays, catering to various medical fields such as spine, hip, knee, sports medicine, and trauma surgery. With facilities located in the United States, France, and Malaysia, Intech is positioned as a one-stop shop for medical device OEMs, delivering both off-the-shelf and custom-made instruments efficiently and cost-effectively.

Groupe 3S

Private Equity Round in 2017
Groupe 3S SAS, founded in 2001 and based in Roissy-en-France, France, specializes in providing a comprehensive range of ground handling and airport management services. The company offers essential services to airlines and airport operators, including passenger and baggage handling, load control, ramp activities, and crew management. Additionally, Groupe 3S delivers airport services such as assistance for persons with disabilities, management of taxi areas, cleaning of airports, aircraft de-icing, and runway maintenance. The organization also engages in industrial cleaning, ultra-cleanliness, facility management, and home support services for individuals. Moreover, it provides aviation security training, dangerous goods handling, and ground handling training courses. Through the synergy of expertise from its subsidiaries, Groupe 3S has established itself as a prominent player in the global services market.

MedLumics

Series B in 2017
Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

The Reefer Group

Private Equity Round in 2016
The Reefer Group SL, based in Alzira, Spain, specializes in the design and manufacture of refrigerated semi-trailers and vehicles for temperature-controlled transportation. The company serves both domestic and international markets, offering a range of products including new and used semi-trailers, trucks, tractor-trailers, removable bodies, and utility vehicles. Its vehicles are suitable for transporting a variety of temperature-sensitive goods such as meat, dairy, fruits, vegetables, flowers, and pharmaceuticals. In addition to manufacturing, The Reefer Group provides spare parts, servicing, repairs, and rebuilding services, as well as after-sales support including liveries, rentals, vehicle upgrades, and training. Established in 2015, the company operates through a comprehensive sales network to meet the needs of its clients.

MS Vacances

Venture Round in 2016
MS Vacances SAS, established in 1992 and located in Nantes, France, specializes in the hospitality sector by providing boarding and lodging services. The company operates holiday homes across France and offers a range of mobile leisure accommodations, incorporating amenities such as camping facilities, indoor pools, bars, restaurants, grocery services, and laundry facilities. Additionally, MS Vacances is known for its premium air travel services in the Atlantic and Mediterranean regions, enhancing the overall holiday experience for its customers.

Mondial Pet Distribution

Venture Round in 2016
Mondial Pet Distribution S.p.A., located in Fossano, Italy, specializes in the distribution of hygiene and personal care products for animals, primarily under the Fortesan brand. The company focuses on providing high-quality products that cater to the needs of pet owners and their animals. As of April 2018, it operates as a subsidiary of Agrifarma S.p.A.

Ipside

Venture Round in 2016
Ipside is a firm that provides comprehensive assistance and advice to clients on patent acquisition, operation, and defense, both in France and internationally. The company specializes in various sectors, including telecommunications, software, aerospace, pharmaceuticals, biotechnology, and optoelectronics. In addition to patent services, Ipside offers litigation and consultancy related to patent law, trademark law, design law, copyright law, and software rights. The firm helps clients develop technical and legal strategies to protect their inventions, ensuring an effective approach to intellectual property that aligns with their overall business objectives.

Orchestra

Acquisition in 2016
Orchestra is an online platform dedicated to the travel industry. It enables professionals to produce, administrate, distribute, and manage leisure offers on many distribution channels. Orchestra is based in Lopera, Spain.

Sogetrel

Private Equity Round in 2016
Sogetrel, S.A.S. is a prominent company specializing in the design, deployment, and maintenance of network infrastructures and digital communication solutions. Established in 1985 and headquartered in Issy les Moulineaux, France, Sogetrel operates branches in Belgium and Switzerland. The company provides a range of services, including the integration of telecommunications networks, IP security systems for video surveillance and access control, and support for smart city projects. Sogetrel serves a diverse clientele across various sectors such as telecommunications, public authorities, defense, transport, and utilities. By focusing on the development of very high-speed networks and offering both customized and turnkey solutions, Sogetrel aims to enhance the quality of life for citizens while promoting efficiency and sustainability in the regions it serves.

REALEASE Capital

Private Equity Round in 2015
REALEASE Capital is a French company based in Puteaux that provides leasing and financing solutions for manufacturers of materials used in videoconferencing and other technological assets. Founded in 1986, the company specializes in the progressive rental of a diverse range of equipment, including IT, telecom, industrial, audiovisual, medical, and digital devices. Through its financial services, REALEASE Capital aims to support businesses in acquiring essential technology without the burdens of outright purchase, thereby facilitating access to innovative tools across various sectors.

Groupe ERGET

Venture Round in 2015
Groupe ERGET SA, founded in 1986 and headquartered in Neuilly-sur-Seine, France, specializes in surveying and loss adjustment services for various sectors, including cargo, property, and liability risks. The company provides technical risk assessments and expertise in fields such as construction, aviation, energy, industrial safety, and product liability. With a workforce of 120 collaborators, including 85 multidisciplinary surveyors, Groupe ERGET has expanded its international presence since 2006, operating teams in Asia, South America, and the West Indies, alongside a joint venture in over 30 African countries. The company has successfully conducted more than 5,500 missions across 115 countries, serving clients that include insurers, brokers, industrialists, and legal professionals. With a reported turnover of 20 million euros, 35% of which is generated from international markets, Groupe ERGET is recognized as a leader in the francophone market and continues to pursue growth opportunities in emerging regions.

ACE Group

Venture Round in 2015
ACE Group is a prominent French mortgage broker specializing in credit brokerage for real estate assets. The company provides a range of services aimed at facilitating mortgage solutions for individuals and businesses seeking to finance property purchases. With a focus on understanding client needs and market conditions, ACE Group aims to deliver tailored financial solutions that support clients in navigating the complexities of real estate financing. By leveraging industry expertise and market insights, ACE Group positions itself as a key player in the mortgage brokerage sector in France.

ACE Group

Private Equity Round in 2015
ACE Group is a prominent French mortgage broker specializing in credit brokerage for real estate assets. The company provides a range of services aimed at facilitating mortgage solutions for individuals and businesses seeking to finance property purchases. With a focus on understanding client needs and market conditions, ACE Group aims to deliver tailored financial solutions that support clients in navigating the complexities of real estate financing. By leveraging industry expertise and market insights, ACE Group positions itself as a key player in the mortgage brokerage sector in France.

Emeraude International

Private Equity Round in 2014
Emeraude International SA is a distributor of polymers and chemicals, specializing in a diverse range of products, including polyolefins and thermoplastics. The company offers blown film extrusion polymers used in agricultural films, food packaging, and flexible packaging, as well as blow molding polymers for beverage and cosmetic containers. Additionally, Emeraude provides pipe extrusion polymers for various applications, including telecommunications, and injection molding polymers for creating household items, garden furniture, and industrial components. With a strong focus on supply chain solutions and tailored logistics, Emeraude International serves a global clientele, primarily in Africa, the Indian subcontinent, Europe, and Southeast Asia. Established in 1986 and headquartered in Paris, France, the company has expanded its presence with additional offices in France and internationally.

Finsecur

Venture Round in 2014
Finsecur S.A. is a French company based in Paris that specializes in the design, manufacture, and maintenance of fire-detection systems. Established in 2000, it offers a range of products including detectors, control panels, and accessories, as well as comprehensive fire alarm systems such as home fire detectors, extinguishing systems, and smoke clearing panels. Additionally, the company provides technical alarms for monitoring defects and anomalies in installations, including alarm panels and sprinkler system monitoring. Finsecur's products cater to various sectors, including clean rooms, telecoms, airports, and military industries. The company has been recognized for its innovation and growth, having received the BPI label Excellence, which connects it with a network of leading French companies in technology.

A2iA

Private Equity Round in 2014
A2iA S.A. specializes in the development of advanced software tools for handwritten and machine-printed text recognition, information extraction, and intelligent document classification. Its product offerings include a2ia Mobility, which supports various workflows such as mobile remote deposit capture and ID verification; a2ia mNote, designed for offline conversion of handwritten notes into digital formats; and a2ia DocumentReader, which extracts data from both structured and unstructured documents. Additional tools include a2ia TextReader for transcribing printed and cursive handwriting, a2ia CheckReader for automated data capture from payment documents, and a2ia FieldReader for extracting information from forms. A2iA caters to a diverse clientele across sectors such as banking, fintech, telecom, healthcare, and government, serving markets in Europe, North America, Latin America, the Middle East, Africa, India, and the Asia Pacific. Founded in 1991 and headquartered in Paris, with an office in New York, A2iA operates as a subsidiary of Mitek Systems, Inc.

Maesa

Venture Round in 2014
Maesa is a company based in Levallois Perret, France, specializing in the design and manufacture of tailor-made perfumes, cosmetics, and promotional products. Founded in 1997, it operates across Europe, Asia, and North America. Maesa focuses on various aspects of product development, including brand identity, industrial design, package design, and graphic design. The company offers turnkey beauty products and home fragrance solutions for retailers and brands, and it also provides packaging components and promotional products for the beauty industry. In addition to its manufacturing capabilities, Maesa serves as a beauty brand incubator, creating exclusive brands and private labels for a range of retail sectors, including mass, drug, and specialty markets.

Thomson Video Networks

Private Equity Round in 2014
Thomson Video Networks SAS specializes in delivering comprehensive video solutions for broadcasters globally, focusing on various platforms including satellite, terrestrial, IPTV, and mobile TV. The company offers a wide range of products, including video compression systems such as HD and SD encoders, multiscreen video systems, and contribution codec platforms. Additionally, it provides processing and multiplexing systems, MPEG stream servers, and video decoding systems tailored for various broadcast applications. Thomson Video Networks also supplies data casting systems, monitoring and switching solutions, and integration and technical support services. Established in 2010 and headquartered in Cesson-Sevigne, France, the company operates as a subsidiary of Harmonic Inc., having previously been part of Grass Valley USA, LLC.

Poxel

Series B in 2014
Poxel S.A. is a biopharmaceutical company based in Lyon, France, focused on developing innovative treatments for metabolic diseases, primarily type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009 as a spin-off from Merck Serono, Poxel is advancing its lead product, Imeglimin, through Phase III clinical trials; this oral anti-diabetic candidate targets organ functions affected by diabetes, such as the pancreas, liver, and muscles. The company is also developing PXL770, currently in Phase IIa trials, which activates the adenosine monophosphate-activated protein kinase (AMPK) to manage energy metabolism, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I trials for NASH. Additionally, Poxel has a licensing agreement with Enyo Pharma for the development of PXL007, an FXR agonist in Phase I studies for hepatitis B and NASH. The company’s pipeline reflects its commitment to addressing critical targets in cellular energy regulation, which are vital for treating metabolic disorders.

Groupe ADF

Private Equity Round in 2014
Groupe ADF SAS is an industrial maintenance and engineering services provider based in Vitrolles, France, founded in 1962. The company specializes in delivering maintenance solutions across various sectors, including aeronautics, space and defense, energy, and oil and gas. Its offerings encompass a wide range of services such as maintenance for the petrochemical and metallurgical industries, naval and port repairs, and pharmaceutical and agro-food sectors. Additionally, Groupe ADF provides turn-key solutions, revamping work, management of statutory stoppage work, and environmental services like waste management and industrial cleaning. The company is also involved in equipment integration and digital transformation to enhance production support and automate business processes.

Genticel

Series D in 2013
Genticel is a French clinical-stage biotechnology company established in 2001 by Benedikt Timmerman. The company specializes in developing innovative immunotherapies aimed at treating viral infections and diseases associated with viruses. Genticel focuses particularly on human papillomavirus (HPV) and HPV-induced conditions, such as cervical cancer. Its research includes advanced therapeutic vaccines and immunotherapy products, including a proprietary technological platform designed to enhance treatment efficacy. Genticel aspires to lead in the immunotherapy sector across various medical indications, with an initial emphasis on addressing the challenges posed by HPV and related health issues.

ITESA

Private Equity Round in 2013
ITESA is an independent distributor based in Marseille, France, specializing in electronic safety equipment for professional clients. Established in 1978, the company offers a comprehensive range of products including radio and bus wired alarm panels, perimeter and volumetric detectors, barriers, sound and light signals, and alarm transmission systems. Additionally, ITESA provides management solutions such as biometric identification systems, intercom products, video surveillance equipment, and fire safety systems. The product portfolio also includes automation solutions, audio equipment like ceiling speakers and microphones, and various accessories. ITESA sells its products through agencies in France and Switzerland, focusing on delivering innovative solutions and high-value services that enhance its partners' market presence.

Poxel

Series B in 2012
Poxel S.A. is a biopharmaceutical company based in Lyon, France, focused on developing innovative treatments for metabolic diseases, primarily type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009 as a spin-off from Merck Serono, Poxel is advancing its lead product, Imeglimin, through Phase III clinical trials; this oral anti-diabetic candidate targets organ functions affected by diabetes, such as the pancreas, liver, and muscles. The company is also developing PXL770, currently in Phase IIa trials, which activates the adenosine monophosphate-activated protein kinase (AMPK) to manage energy metabolism, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I trials for NASH. Additionally, Poxel has a licensing agreement with Enyo Pharma for the development of PXL007, an FXR agonist in Phase I studies for hepatitis B and NASH. The company’s pipeline reflects its commitment to addressing critical targets in cellular energy regulation, which are vital for treating metabolic disorders.

OCEAN SAS

Venture Round in 2011
OCEAN SAS specializes in vehicle tracking solutions in France, focusing on the management of vehicle fleets and the monitoring of on-the-road activities for its clients. The company's tracking system provides essential information about vehicles and drivers, offering customized management solutions that include features such as connectivity to personal digital assistants, in-car printers, WAP access, vehicle neutralization, driver identification keys, data transfer, and bespoke applications. Established in 2003 and headquartered in Clichy, France, OCEAN SAS has positioned itself as a leader in the vehicle tracking industry. As of 2015, it operates as a subsidiary of Orange Business Services.

Novamex SA

Private Equity Round in 2011
Novamex S.A. produces natural and eco-friendly cleaning, washing, and personal hygiene products to individuals and companies in France. It offers washing powders and liquids, cleaning liquids, shampoos, moisturizers, and hair conditioning products.

SuperSonic Imagine

Series C in 2010
SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

Garden Price

Venture Round in 2010
Garden Price is a Les Nouvelles Jardineries, a Maurepas, France-based chain of low-cost garden stores.

Implanet

Series D in 2010
Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

Poxel

Series A in 2010
Poxel S.A. is a biopharmaceutical company based in Lyon, France, focused on developing innovative treatments for metabolic diseases, primarily type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009 as a spin-off from Merck Serono, Poxel is advancing its lead product, Imeglimin, through Phase III clinical trials; this oral anti-diabetic candidate targets organ functions affected by diabetes, such as the pancreas, liver, and muscles. The company is also developing PXL770, currently in Phase IIa trials, which activates the adenosine monophosphate-activated protein kinase (AMPK) to manage energy metabolism, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I trials for NASH. Additionally, Poxel has a licensing agreement with Enyo Pharma for the development of PXL007, an FXR agonist in Phase I studies for hepatitis B and NASH. The company’s pipeline reflects its commitment to addressing critical targets in cellular energy regulation, which are vital for treating metabolic disorders.

Implanet

Series C in 2010
Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

Genticel

Series C in 2010
Genticel is a French clinical-stage biotechnology company established in 2001 by Benedikt Timmerman. The company specializes in developing innovative immunotherapies aimed at treating viral infections and diseases associated with viruses. Genticel focuses particularly on human papillomavirus (HPV) and HPV-induced conditions, such as cervical cancer. Its research includes advanced therapeutic vaccines and immunotherapy products, including a proprietary technological platform designed to enhance treatment efficacy. Genticel aspires to lead in the immunotherapy sector across various medical indications, with an initial emphasis on addressing the challenges posed by HPV and related health issues.

Smile

Venture Round in 2010
Smile is a provider of software integration and maintenance services based in Levallois-Perret, France. The company specializes in open source solutions, aiming to unlock innovation potential for businesses by leveraging its technical and business expertise. Smile's offerings encompass a wide range of areas, including digital evolution, business applications, embedded technologies, the Internet of Things (IoT), and infrastructure management. By focusing on these domains, Smile helps organizations optimize their operations and enhance their digital capabilities.

Implanet

Series B in 2009
Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

SuperSonic Imagine

Series B in 2008
SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

EOS Imaging

Venture Round in 2007
EOS Imaging SA is a medical technology company based in Paris, France, specializing in low-dose 2D/3D imaging and software solutions for osteo-articular conditions and orthopedic surgeries. The company develops and markets the EOS imaging system, which produces full-body, stereo-radiographic images of patients in functional positions, tailored to the specific needs of orthopedic surgeons and radiologists. Its product offerings include EOSedge, a high-quality X-ray system, sterEOS, a 3D modeling workstation for precise skeletal analysis, and EOSapps, online surgical planning solutions based on real-time imaging. Additionally, EOS Imaging creates planning software for knee and hip surgeries and manufactures patient-specific cutting guides for orthopedic procedures. The company operates globally, with a presence in Europe, the Middle East, Africa, North America, the Asia-Pacific, and Latin America, and has obtained marketing authorization for its systems in 48 countries. Founded in 1989, EOS Imaging was previously known as biospace med before rebranding in 2010.

Implanet

Series A in 2007
Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

Domain Therapeutics

Series C in 2006
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Cytomics Pharmaceuticals

Series B in 2006
Cytomics Systems is a French private company that offers bio-pharmacology services. The company uses Yeast Micro-Lab technology, a protenomics tool, which enables to follow in-vitro deterioration of proteins. Cytomics Systems's research and development focuses on fungicidal infections, inflammatory illnesses, and cancers. Cytomics Systems, S.A was founded in 2000 and is based in Gif-sur-Yvette, France.

Cellectis

Series C in 2005
Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, focused on developing innovative immuno-oncology therapies using gene-edited T-cells. The company specializes in allogeneic Chimeric Antigen Receptor T-cell (CAR-T) products, with a portfolio that includes several product candidates targeting various hematologic malignancies. Notable candidates include UCART19, aimed at treating CD19-expressing hematologic cancers such as acute lymphoblastic leukemia; UCART123 for acute myeloid leukemia; and UCARTCS1 and ALLO-715 for multiple myeloma. In addition to its therapeutic efforts, Cellectis also produces high oleic soybean oil and other soybean products, as well as fiber wheat. The company collaborates with various strategic partners, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to advance its mission of eradicating cancer through cutting-edge gene-editing technologies.

Nautilus Biotech

Venture Round in 2005
Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.

Domain Therapeutics

Series B in 2004
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Cellectis

Series B in 2002
Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, focused on developing innovative immuno-oncology therapies using gene-edited T-cells. The company specializes in allogeneic Chimeric Antigen Receptor T-cell (CAR-T) products, with a portfolio that includes several product candidates targeting various hematologic malignancies. Notable candidates include UCART19, aimed at treating CD19-expressing hematologic cancers such as acute lymphoblastic leukemia; UCART123 for acute myeloid leukemia; and UCARTCS1 and ALLO-715 for multiple myeloma. In addition to its therapeutic efforts, Cellectis also produces high oleic soybean oil and other soybean products, as well as fiber wheat. The company collaborates with various strategic partners, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to advance its mission of eradicating cancer through cutting-edge gene-editing technologies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.